Inhibition of Histone Deacetylases (HDACs) and mTOR Signaling: Novel Strategies Toward the Treatment of Prostate Cancer
Abstract
During the past year I have setup a transplant androgen sensitive and castrate resistant prostate tumor mouse model for pre-clinical evaluation of novel targeted therapies. Further, this tumor is derived from a transgenic mouse of prostate cancer and all studies are performed in immune-competent animals. We have currently submitted 2 manuscripts, the first describing the creation of the transplant tumor model, and the second describing the increased therapeutic efficacy of HDAC/mTOR inhibitor combination for the treatment of advanced and castrate resistant prostate cancer. We also describe that increased inhibition of androgen receptor and HIF-1 alpha signaling as a major reason for greater therapeutic efficacy by combination therapy. Lastly, this manuscript demonstrates that microRNA may provide novel biomarkers for indication of therapy response. This work is inline with a current clinical trial under recruitment to treat patients with HDAC/mTOR inhibitor combination who have castrate resistant prostate cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2011
- Accession Number
- ADA551610
Entities
People
- Leigh Ellis
Organizations
- Health Research, Incorporated